187 related articles for article (PubMed ID: 36220994)
1. Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.
Chen J; Yang J; Wang W; Guo D; Zhang C; Wang S; Lu X; Huang X; Wang P; Zhang G; Zhang J; Wang J; Cai Z
Cell Mol Immunol; 2022 Nov; 19(11):1290-1301. PubMed ID: 36220994
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
Xin B; Yang M; Wu P; Du L; Deng X; Hui E; Feng GS
Hepatology; 2022 Sep; 76(3):630-645. PubMed ID: 34860431
[TBL] [Abstract][Full Text] [Related]
3. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
4. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
6. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages.
Zhang Y; Wu L; Li Z; Zhang W; Luo F; Chu Y; Chen G
Biomacromolecules; 2018 Jun; 19(6):2098-2108. PubMed ID: 29634251
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
8. Synergism of
Wen X; Zeng X; Liu J; Zhang Y; Shi C; Wu X; Zhuang R; Chen X; Zhang X; Guo Z
Bioconjug Chem; 2022 Nov; 33(11):2170-2179. PubMed ID: 36256849
[TBL] [Abstract][Full Text] [Related]
9. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.
Wen X; Zeng X; Cheng X; Zeng X; Liu J; Zhang Y; Li Y; Chen H; Huang J; Guo Z; Chen X; Zhang X
Mol Pharm; 2022 Oct; 19(10):3612-3622. PubMed ID: 35652897
[TBL] [Abstract][Full Text] [Related]
10. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
12. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
[TBL] [Abstract][Full Text] [Related]
13. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.
van Gulijk M; van Krimpen A; Schetters S; Eterman M; van Elsas M; Mankor J; Klaase L; de Bruijn M; van Nimwegen M; van Tienhoven T; van Ijcken W; Boon L; van der Schoot J; Verdoes M; Scheeren F; van der Burg SH; Lambrecht BN; Stadhouders R; Dammeijer F; Aerts J; van Hall T
Sci Immunol; 2023 May; 8(83):eabn6173. PubMed ID: 37205768
[TBL] [Abstract][Full Text] [Related]
15. Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy.
Wang Y; Zhou SK; Wang Y; Lu ZD; Zhang Y; Xu CF; Wang J
Nat Commun; 2023 Apr; 14(1):1993. PubMed ID: 37031188
[TBL] [Abstract][Full Text] [Related]
16. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Ye L; Xing Y; Hu J; Xi T
Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
[TBL] [Abstract][Full Text] [Related]
17. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M; Zorea J; Jagadeeshan S; Shnerb AB; Mathukkada S; Bouaoud J; Michon L; Novoplansky O; Badarni M; Cohen L; Yegodayev KM; Tzadok S; Rotblat B; Brezina L; Mock A; Karabajakian A; Fayette J; Cohen I; Cooks T; Allon I; Dimitstein O; Joshua B; Kong D; Voronov E; Scaltriti M; Carmi Y; Conde-Lopez C; Hess J; Kurth I; Morris LGT; Saintigny P; Elkabets M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292516
[TBL] [Abstract][Full Text] [Related]
18. A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect.
Wen X; Shi C; Zeng X; Zhao L; Yao L; Liu Z; Feng L; Zhang D; Huang J; Li Y; Lin Q; Chen H; Zhuang R; Chen X; Zhang X; Guo Z
Clin Cancer Res; 2022 Jul; 28(13):2923-2937. PubMed ID: 35320358
[TBL] [Abstract][Full Text] [Related]
19. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
20. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
Front Immunol; 2021; 12():619209. PubMed ID: 33790893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
